Fas cell surface death receptor/Fas ligand genetic variants in gastric cancer patients: A case-control study

Background & objectives: Various studies have suggested a correlation between Fas cell surface death receptor/Fas ligand (FAS/FASL) variants and multiple types of cancers. The present study aimed to investigate the association between FAS-670A/G and FASL-844C/T and the synergistic effects of bot...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Indian Journal of Medical Research 2022-07, Vol.156 (1), p.77-82
Hauptverfasser: Asgari, Rezvan, Bidmeshkipour, Ali, Mansouri, Kamran, Bakhtiari, Mitra, Mozafari, Hadi, Abdolmaleki, Amir
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 82
container_issue 1
container_start_page 77
container_title Indian Journal of Medical Research
container_volume 156
creator Asgari, Rezvan
Bidmeshkipour, Ali
Mansouri, Kamran
Bakhtiari, Mitra
Mozafari, Hadi
Abdolmaleki, Amir
description Background & objectives: Various studies have suggested a correlation between Fas cell surface death receptor/Fas ligand (FAS/FASL) variants and multiple types of cancers. The present study aimed to investigate the association between FAS-670A/G and FASL-844C/T and the synergistic effects of both variants on the risk of gastric cancer (GC) in the Kurdish population of west of Iran. Methods: This study was conducted by polymerase chain reaction-restriction fragment length polymorphism technique using MvaI and BsrDI restriction enzymes in 98 GC patients and 103 healthy control individuals. Results: According to the obtained results, a significant association (P=0.008) of FASL polymorphism among GC patients and the control group was detected. Furthermore, no significant differences were found in the FAS polymorphism frequencies between GC patients and the control group. Codominant and dominant models in FASL polymorphism showed significant protective effects against GC [odds ratio (OR)=0.307, 95% confidence interval (CI) (0.134-0.705), P=0.005; OR=0.205, 95% CI (0.058-0.718), P=0.013 and OR=0.295, 95% CI (0.129-0.673), P=0.004 for models of codominant CC vs. CT, codominant CC vs. TT and dominant, respectively]. Furthermore, the presence of both FAS-670G and FASL-844T alleles represented a significant protective effect against GC occurrence [OR=0.420, 95% CI (0.181-0.975), P=0.043]. Interpretation & conclusions: So far, we believe this is the first study, the results of which suggest that FASL gene variation and its synergistic effects with FAS gene could be associated with the risk of GC in the Kurdish population in the west of Iran.
doi_str_mv 10.4103/ijmr.IJMR_2058_19
format Article
fullrecord <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9903394</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A730768412</galeid><sourcerecordid>A730768412</sourcerecordid><originalsourceid>FETCH-LOGICAL-c486r-659f9e25429f6751a8b0241cea8be7a238688628e976943266158cf2510d5d983</originalsourceid><addsrcrecordid>eNp9kktv1DAUhSMEomXgB7BBkdiwydSPxA8WSKOKQlEREoIFqyvXuZl6mrEHO-mo_x6nMy0tAuSFrXu_e2wfnaJ4Scm8poQfudU6zk8_ff4KjDQKqH5UHBItm0pTWT--OdOq0VQcFM9SWhFCNZP6aXHABWV1rcVh0Z-YVFrs-zKNsTMWyxbNcFFGtLgZQjya-r1bGt-WS_Q4OFtemeiMH1LpfLk0aYi5Zo23GMuNGRzm1ttykUsJKxv8EENWH8b2-nnxpDN9whf7fVZ8P3n_7fhjdfblw-nx4qyytRKxEo3uNLKmZroTsqFGnRNWU4v5gNIwroRSginUUuiaMyFoo2zHGkraptWKz4p3O93NeL7G1uYXRdPDJrq1idcQjIOHHe8uYBmuQGvCeZacFW_2AjH8HDENsHZpcsl4DGMCJqkgSnMhMvr6D3QVxujz94BTziUjNZP_o5hsBCEy_-c3tTQ9gvNdyK-z09WwkDwzqqYsU_O_UHm1uHbZb-xcrj8YoLsBG0NKEbs7JyiBKUgwBQnuBynPvLpv4d3EbXIy8GMHbEM_YEyX_bjFCJm99GH7b2WQEnKmYHIT9pmDm8zBbeb4Lyc449I</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2756007628</pqid></control><display><type>article</type><title>Fas cell surface death receptor/Fas ligand genetic variants in gastric cancer patients: A case-control study</title><source>MEDLINE</source><source>Medknow Open Access Medical Journals</source><source>PubMed Central Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Asgari, Rezvan ; Bidmeshkipour, Ali ; Mansouri, Kamran ; Bakhtiari, Mitra ; Mozafari, Hadi ; Abdolmaleki, Amir</creator><creatorcontrib>Asgari, Rezvan ; Bidmeshkipour, Ali ; Mansouri, Kamran ; Bakhtiari, Mitra ; Mozafari, Hadi ; Abdolmaleki, Amir</creatorcontrib><description>Background &amp; objectives: Various studies have suggested a correlation between Fas cell surface death receptor/Fas ligand (FAS/FASL) variants and multiple types of cancers. The present study aimed to investigate the association between FAS-670A/G and FASL-844C/T and the synergistic effects of both variants on the risk of gastric cancer (GC) in the Kurdish population of west of Iran. Methods: This study was conducted by polymerase chain reaction-restriction fragment length polymorphism technique using MvaI and BsrDI restriction enzymes in 98 GC patients and 103 healthy control individuals. Results: According to the obtained results, a significant association (P=0.008) of FASL polymorphism among GC patients and the control group was detected. Furthermore, no significant differences were found in the FAS polymorphism frequencies between GC patients and the control group. Codominant and dominant models in FASL polymorphism showed significant protective effects against GC [odds ratio (OR)=0.307, 95% confidence interval (CI) (0.134-0.705), P=0.005; OR=0.205, 95% CI (0.058-0.718), P=0.013 and OR=0.295, 95% CI (0.129-0.673), P=0.004 for models of codominant CC vs. CT, codominant CC vs. TT and dominant, respectively]. Furthermore, the presence of both FAS-670G and FASL-844T alleles represented a significant protective effect against GC occurrence [OR=0.420, 95% CI (0.181-0.975), P=0.043]. Interpretation &amp; conclusions: So far, we believe this is the first study, the results of which suggest that FASL gene variation and its synergistic effects with FAS gene could be associated with the risk of GC in the Kurdish population in the west of Iran.</description><identifier>ISSN: 0971-5916</identifier><identifier>EISSN: 0975-9174</identifier><identifier>DOI: 10.4103/ijmr.IJMR_2058_19</identifier><identifier>PMID: 36124496</identifier><language>eng</language><publisher>India: Wolters Kluwer India Pvt. Ltd</publisher><subject>Case-Control Studies ; Cell receptors ; Fas Ligand Protein - genetics ; fas Receptor - genetics ; Gastric cancer ; Genetic aspects ; Genetic Predisposition to Disease ; Genotype ; Health aspects ; Humans ; Ligands ; Original ; Physiological aspects ; Polymorphism ; Polymorphism, Single Nucleotide - genetics ; Risk factors ; Single nucleotide polymorphisms ; Stomach cancer ; Stomach Neoplasms - genetics</subject><ispartof>Indian Journal of Medical Research, 2022-07, Vol.156 (1), p.77-82</ispartof><rights>COPYRIGHT 2022 Medknow Publications and Media Pvt. Ltd.</rights><rights>2022. This article is published under (http://creativecommons.org/licenses/by-nc-sa/3.0/) (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright: © 2022 Indian Journal of Medical Research 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c486r-659f9e25429f6751a8b0241cea8be7a238688628e976943266158cf2510d5d983</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9903394/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9903394/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,724,777,781,882,27905,27906,53772,53774</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36124496$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Asgari, Rezvan</creatorcontrib><creatorcontrib>Bidmeshkipour, Ali</creatorcontrib><creatorcontrib>Mansouri, Kamran</creatorcontrib><creatorcontrib>Bakhtiari, Mitra</creatorcontrib><creatorcontrib>Mozafari, Hadi</creatorcontrib><creatorcontrib>Abdolmaleki, Amir</creatorcontrib><title>Fas cell surface death receptor/Fas ligand genetic variants in gastric cancer patients: A case-control study</title><title>Indian Journal of Medical Research</title><addtitle>Indian J Med Res</addtitle><description>Background &amp; objectives: Various studies have suggested a correlation between Fas cell surface death receptor/Fas ligand (FAS/FASL) variants and multiple types of cancers. The present study aimed to investigate the association between FAS-670A/G and FASL-844C/T and the synergistic effects of both variants on the risk of gastric cancer (GC) in the Kurdish population of west of Iran. Methods: This study was conducted by polymerase chain reaction-restriction fragment length polymorphism technique using MvaI and BsrDI restriction enzymes in 98 GC patients and 103 healthy control individuals. Results: According to the obtained results, a significant association (P=0.008) of FASL polymorphism among GC patients and the control group was detected. Furthermore, no significant differences were found in the FAS polymorphism frequencies between GC patients and the control group. Codominant and dominant models in FASL polymorphism showed significant protective effects against GC [odds ratio (OR)=0.307, 95% confidence interval (CI) (0.134-0.705), P=0.005; OR=0.205, 95% CI (0.058-0.718), P=0.013 and OR=0.295, 95% CI (0.129-0.673), P=0.004 for models of codominant CC vs. CT, codominant CC vs. TT and dominant, respectively]. Furthermore, the presence of both FAS-670G and FASL-844T alleles represented a significant protective effect against GC occurrence [OR=0.420, 95% CI (0.181-0.975), P=0.043]. Interpretation &amp; conclusions: So far, we believe this is the first study, the results of which suggest that FASL gene variation and its synergistic effects with FAS gene could be associated with the risk of GC in the Kurdish population in the west of Iran.</description><subject>Case-Control Studies</subject><subject>Cell receptors</subject><subject>Fas Ligand Protein - genetics</subject><subject>fas Receptor - genetics</subject><subject>Gastric cancer</subject><subject>Genetic aspects</subject><subject>Genetic Predisposition to Disease</subject><subject>Genotype</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Ligands</subject><subject>Original</subject><subject>Physiological aspects</subject><subject>Polymorphism</subject><subject>Polymorphism, Single Nucleotide - genetics</subject><subject>Risk factors</subject><subject>Single nucleotide polymorphisms</subject><subject>Stomach cancer</subject><subject>Stomach Neoplasms - genetics</subject><issn>0971-5916</issn><issn>0975-9174</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9kktv1DAUhSMEomXgB7BBkdiwydSPxA8WSKOKQlEREoIFqyvXuZl6mrEHO-mo_x6nMy0tAuSFrXu_e2wfnaJ4Scm8poQfudU6zk8_ff4KjDQKqH5UHBItm0pTWT--OdOq0VQcFM9SWhFCNZP6aXHABWV1rcVh0Z-YVFrs-zKNsTMWyxbNcFFGtLgZQjya-r1bGt-WS_Q4OFtemeiMH1LpfLk0aYi5Zo23GMuNGRzm1ttykUsJKxv8EENWH8b2-nnxpDN9whf7fVZ8P3n_7fhjdfblw-nx4qyytRKxEo3uNLKmZroTsqFGnRNWU4v5gNIwroRSginUUuiaMyFoo2zHGkraptWKz4p3O93NeL7G1uYXRdPDJrq1idcQjIOHHe8uYBmuQGvCeZacFW_2AjH8HDENsHZpcsl4DGMCJqkgSnMhMvr6D3QVxujz94BTziUjNZP_o5hsBCEy_-c3tTQ9gvNdyK-z09WwkDwzqqYsU_O_UHm1uHbZb-xcrj8YoLsBG0NKEbs7JyiBKUgwBQnuBynPvLpv4d3EbXIy8GMHbEM_YEyX_bjFCJm99GH7b2WQEnKmYHIT9pmDm8zBbeb4Lyc449I</recordid><startdate>20220701</startdate><enddate>20220701</enddate><creator>Asgari, Rezvan</creator><creator>Bidmeshkipour, Ali</creator><creator>Mansouri, Kamran</creator><creator>Bakhtiari, Mitra</creator><creator>Mozafari, Hadi</creator><creator>Abdolmaleki, Amir</creator><general>Wolters Kluwer India Pvt. Ltd</general><general>Medknow Publications and Media Pvt. Ltd</general><general>Scientific Scholar</general><general>Wolters Kluwer - Medknow</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>M2P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>S0X</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20220701</creationdate><title>Fas cell surface death receptor/Fas ligand genetic variants in gastric cancer patients: A case-control study</title><author>Asgari, Rezvan ; Bidmeshkipour, Ali ; Mansouri, Kamran ; Bakhtiari, Mitra ; Mozafari, Hadi ; Abdolmaleki, Amir</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c486r-659f9e25429f6751a8b0241cea8be7a238688628e976943266158cf2510d5d983</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Case-Control Studies</topic><topic>Cell receptors</topic><topic>Fas Ligand Protein - genetics</topic><topic>fas Receptor - genetics</topic><topic>Gastric cancer</topic><topic>Genetic aspects</topic><topic>Genetic Predisposition to Disease</topic><topic>Genotype</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Ligands</topic><topic>Original</topic><topic>Physiological aspects</topic><topic>Polymorphism</topic><topic>Polymorphism, Single Nucleotide - genetics</topic><topic>Risk factors</topic><topic>Single nucleotide polymorphisms</topic><topic>Stomach cancer</topic><topic>Stomach Neoplasms - genetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Asgari, Rezvan</creatorcontrib><creatorcontrib>Bidmeshkipour, Ali</creatorcontrib><creatorcontrib>Mansouri, Kamran</creatorcontrib><creatorcontrib>Bakhtiari, Mitra</creatorcontrib><creatorcontrib>Mozafari, Hadi</creatorcontrib><creatorcontrib>Abdolmaleki, Amir</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Indian Journal of Medical Research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Asgari, Rezvan</au><au>Bidmeshkipour, Ali</au><au>Mansouri, Kamran</au><au>Bakhtiari, Mitra</au><au>Mozafari, Hadi</au><au>Abdolmaleki, Amir</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Fas cell surface death receptor/Fas ligand genetic variants in gastric cancer patients: A case-control study</atitle><jtitle>Indian Journal of Medical Research</jtitle><addtitle>Indian J Med Res</addtitle><date>2022-07-01</date><risdate>2022</risdate><volume>156</volume><issue>1</issue><spage>77</spage><epage>82</epage><pages>77-82</pages><issn>0971-5916</issn><eissn>0975-9174</eissn><abstract>Background &amp; objectives: Various studies have suggested a correlation between Fas cell surface death receptor/Fas ligand (FAS/FASL) variants and multiple types of cancers. The present study aimed to investigate the association between FAS-670A/G and FASL-844C/T and the synergistic effects of both variants on the risk of gastric cancer (GC) in the Kurdish population of west of Iran. Methods: This study was conducted by polymerase chain reaction-restriction fragment length polymorphism technique using MvaI and BsrDI restriction enzymes in 98 GC patients and 103 healthy control individuals. Results: According to the obtained results, a significant association (P=0.008) of FASL polymorphism among GC patients and the control group was detected. Furthermore, no significant differences were found in the FAS polymorphism frequencies between GC patients and the control group. Codominant and dominant models in FASL polymorphism showed significant protective effects against GC [odds ratio (OR)=0.307, 95% confidence interval (CI) (0.134-0.705), P=0.005; OR=0.205, 95% CI (0.058-0.718), P=0.013 and OR=0.295, 95% CI (0.129-0.673), P=0.004 for models of codominant CC vs. CT, codominant CC vs. TT and dominant, respectively]. Furthermore, the presence of both FAS-670G and FASL-844T alleles represented a significant protective effect against GC occurrence [OR=0.420, 95% CI (0.181-0.975), P=0.043]. Interpretation &amp; conclusions: So far, we believe this is the first study, the results of which suggest that FASL gene variation and its synergistic effects with FAS gene could be associated with the risk of GC in the Kurdish population in the west of Iran.</abstract><cop>India</cop><pub>Wolters Kluwer India Pvt. Ltd</pub><pmid>36124496</pmid><doi>10.4103/ijmr.IJMR_2058_19</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0971-5916
ispartof Indian Journal of Medical Research, 2022-07, Vol.156 (1), p.77-82
issn 0971-5916
0975-9174
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9903394
source MEDLINE; Medknow Open Access Medical Journals; PubMed Central Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central
subjects Case-Control Studies
Cell receptors
Fas Ligand Protein - genetics
fas Receptor - genetics
Gastric cancer
Genetic aspects
Genetic Predisposition to Disease
Genotype
Health aspects
Humans
Ligands
Original
Physiological aspects
Polymorphism
Polymorphism, Single Nucleotide - genetics
Risk factors
Single nucleotide polymorphisms
Stomach cancer
Stomach Neoplasms - genetics
title Fas cell surface death receptor/Fas ligand genetic variants in gastric cancer patients: A case-control study
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T12%3A16%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Fas%20cell%20surface%20death%20receptor/Fas%20ligand%20genetic%20variants%20in%20gastric%20cancer%20patients:%20A%20case-control%20study&rft.jtitle=Indian%20Journal%20of%20Medical%20Research&rft.au=Asgari,%20Rezvan&rft.date=2022-07-01&rft.volume=156&rft.issue=1&rft.spage=77&rft.epage=82&rft.pages=77-82&rft.issn=0971-5916&rft.eissn=0975-9174&rft_id=info:doi/10.4103/ijmr.IJMR_2058_19&rft_dat=%3Cgale_pubme%3EA730768412%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2756007628&rft_id=info:pmid/36124496&rft_galeid=A730768412&rfr_iscdi=true